To include your compound in the COVID-19 Resource Center, submit it here.

Chugai's IL-6 receptor mAb meets in Phase III for rare CNS disorder

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said satralizumab (SA237, RG6168) as monotherapy met the primary endpoint in the Phase III SAkuraStar trial to treat neuromyelitis optica spectrum disorder (NMOSD). The company plans

Read the full 313 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE